Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010

Author(s): Meza R, Meernik C, Jeon J, Cote ML


Background Lung cancer (LC) incidence in the United States (US) continues to decrease but with significant differences by histology, gender and race. Whereas squamous, large and small cell carcinoma rates have been decreasing since the mid-80s, adenocarcinoma rates remain stable in males and continue to increase in females, with large racial disparities. We analyzed LC incidence trends by histology in the US with an emphasis on gender and racial differences. Methods LC incidence rates from 1973–2010 were obtained from the SEER cancer registry. Age-adjusted incidence trends of five major histological types by gender and race were evaluated using joinpoint regression. Trends of LC histology and stage distributions from 2005–2010 were analyzed. Results US LC incidence varies by histology. Squamous, large and small cell carcinoma rates continue to decrease for all gender/race combinations, whereas adenocarcinoma rates remain relatively constant in males and increasing in females. An apparent recent increase in the incidence of squamous cell carcinoma and adenocarcinoma since 2005 can be explained by a concomitant decrease in the number of cases classified as other non-small cell carcinoma. Black males continue to be disproportionally affected by squamous LCs, and blacks continue to be diagnosed with more advanced cancers than whites. Conclusions LC incidence by histology continues to change over time. Additional variations are expected as screening becomes disseminated. It is important to continue to monitor LC rates to evaluate the impact of screening on current trends, assess the continuing benefits of tobacco control, and focus efforts on reducing racial disparities.

Similar Articles

Trends in incidence of small cell lung cancer and all lung cancer

Author(s): Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, et al.

Current small cell lung cancer treatment in China

Author(s): Shi Y, Xing P, Fan Y, Zhang X, Hu C, et al.

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1pathway

Author(s): Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Author(s): Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, et al.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Author(s): Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Author(s): Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, et al.

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Author(s): Muenst S, Schaerli AR, Gao F, Däster S, Trella E, et al.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

Author(s): Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.